Yingli Pharma announce promising topline results of a Phase II registration study for treatment of relapsed/refractory follicular lymphoma with the once daily oral PI3Kδ inhibitor, linperlisib ...Middle East

PR Newswire - News
Yingli Pharma announce promising topline results of a Phase II registration study for treatment of relapsed/refractory follicular lymphoma with the once daily oral PI3Kδ inhibitor, linperlisib
Linperlisib provides significant clinical improvement in the treatment for patients with relapsed and/or refractory follicular lymphoma Linperlisib has a differentiated and well manageable safety profile SHANGHAI, March 31, 2021 /PRNewswire/ -- Shanghai Yingli Pharmaceutical Co., Ltd....

Read More Details
Finally We wish PressBee provided you with enough information of ( Yingli Pharma announce promising topline results of a Phase II registration study for treatment of relapsed/refractory follicular lymphoma with the once daily oral PI3Kδ inhibitor, linperlisib )

Apple Storegoogle play

Also on site :